Wordt geladen...

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

With an explosion of available treatments for metastatic renal cell carcinoma (mRCC) in recent years, it is important to recognize that approved targeted therapies fall broadly into only two mechanistic categories. The first category, vascular endothelial growth factor (VEGF)-directed therapies, inc...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Pal, Sumanta Kumar, Figlin, Robert A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2011
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3253822/
https://ncbi.nlm.nih.gov/pubmed/21484496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-011-0172-y
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!